{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:58:01Z","timestamp":1790665081845,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"DOI":"10.1007\/s00330-026-12918-5","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:34:23Z","timestamp":1790616863000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and MRI characteristics of germline pathogenic variant carriers diagnosed with prostate cancer"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9123-4010","authenticated-orcid":false,"given":"Rory L.","family":"Cochran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhangi","family":"Parameswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabih","family":"Nakrour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumyadeep","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman","family":"Elshikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miraj","family":"Rawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximillian","family":"Pohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuttaphon","family":"Aleenajitpong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onofrio A.","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirkasra","family":"Mojtahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley R.","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda H.","family":"Rodgers-Fouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0993-1947","authenticated-orcid":false,"given":"Mukesh G.","family":"Harisinghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7940-4558","authenticated-orcid":false,"given":"Keyan","family":"Salari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"12918_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"12918_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN et al (2025) Cancer statistics, 2025. CA Cancer J Clin 75:10\u201345. https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"CA Cancer J Clin"},{"key":"12918_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jama.2015.17703","volume":"315","author":"LA Mucci","year":"2016","unstructured":"Mucci LA, Hjelmborg JB, Harris JR et al (2016) Familial risk and heritability of cancer among twins in Nordic countries. JAMA 315:68. https:\/\/doi.org\/10.1001\/jama.2015.17703","journal-title":"JAMA"},{"key":"12918_CR4","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1038\/s41588-023-01534-4","volume":"55","author":"A Wang","year":"2023","unstructured":"Wang A, Shen J, Rodriguez AA et al (2023) Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. Nat Genet 55:2065\u20132074. https:\/\/doi.org\/10.1038\/s41588-023-01534-4","journal-title":"Nat Genet"},{"key":"12918_CR5","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","volume":"31","author":"E Castro","year":"2013","unstructured":"Castro E, Goh C, Olmos D et al (2013) Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 31:1748\u20131757. https:\/\/doi.org\/10.1200\/JCO.2012.43.1882","journal-title":"J Clin Oncol"},{"key":"12918_CR6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/nejmoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF et al (2016) Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med 375:443\u2013453. https:\/\/doi.org\/10.1056\/nejmoa1603144","journal-title":"N Engl J Med"},{"key":"12918_CR7","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1200\/JCO.2023.41.6_suppl.390","volume":"41","author":"A Couvillon","year":"2023","unstructured":"Couvillon A, Turkbey B, Choyke PL et al (2023) Inherited risk for prostate cancer (PCa): following the natural history of men with high-risk genetics using multiparametric MRI (mpMRI). J Clin Oncol 41:390\u2013390. https:\/\/doi.org\/10.1200\/JCO.2023.41.6_suppl.390","journal-title":"J Clin Oncol"},{"key":"12918_CR8","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.euo.2024.01.015","volume":"7","author":"AE Amini","year":"2024","unstructured":"Amini AE, Hunter AE, Almashad A et al (2024) Magnetic resonance imaging\u2013based prostate cancer screening in carriers of pathogenic germline mutations: interim results from the initial screening round of the prostate cancer genetic risk evaluation and screening study. Eur Urol Oncol 7:1358\u20131366. https:\/\/doi.org\/10.1016\/j.euo.2024.01.015","journal-title":"Eur Urol Oncol"},{"key":"12918_CR9","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/nejmoa2407934","volume":"392","author":"JK McHugh","year":"2025","unstructured":"McHugh JK, Bancroft EK, Saunders E et al (2025) Assessment of a polygenic risk score in screening for prostate cancer. N Engl J Med 392:1406\u20131417. https:\/\/doi.org\/10.1056\/nejmoa2407934","journal-title":"N Engl J Med"},{"key":"12918_CR10","doi-asserted-by":"publisher","first-page":"236","DOI":"10.6004\/jnccn.2023.0014","volume":"21","author":"KA Moses","year":"2023","unstructured":"Moses KA, Sprenkle PC, Bahler C et al (2023) NCCN Guidelines\u00ae Insights: prostate cancer early detection, version 1.2023: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw 21:236\u2013246. https:\/\/doi.org\/10.6004\/jnccn.2023.0014","journal-title":"J Natl Compr Cancer Netw"},{"key":"12918_CR11","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0022-5347(17)37393-7","volume":"147","author":"MC Benson","year":"1992","unstructured":"Benson MC, Seong Whang I, Pantuck A et al (1992) Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 147:815\u2013816. https:\/\/doi.org\/10.1016\/S0022-5347(17)37393-7","journal-title":"J Urol"},{"key":"12918_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41391-017-0024-7","volume":"21","author":"T Nordstr\u00f6m","year":"2018","unstructured":"Nordstr\u00f6m T, Akre O, Aly M et al (2018) Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer Prostatic Dis 21:57\u201363. https:\/\/doi.org\/10.1038\/s41391-017-0024-7","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"12918_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41391-022-00549-y","volume":"26","author":"JW Frisbie","year":"2023","unstructured":"Frisbie JW, Van Besien AJ, Lee A et al (2023) PSA density is complementary to prostate MP-MRI PI-RADS scoring system for risk stratification of clinically significant prostate cancer. Prostate Cancer Prostatic Dis 26:347\u2013352. https:\/\/doi.org\/10.1038\/s41391-022-00549-y","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"12918_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2025.107189","volume":"92","author":"RL Cochran","year":"2026","unstructured":"Cochran RL, Mercaldo ND, Nakrour N et al (2026) Comparing conventional, peripheral, and transition zone prostate-specific antigen densities for the detection of clinically significant prostate cancer. Clin Radiol 92:107189. https:\/\/doi.org\/10.1016\/j.crad.2025.107189","journal-title":"Clin Radiol"},{"key":"12918_CR15","doi-asserted-by":"publisher","unstructured":"Esengur OT, Stevenson E, Stecko H et al (2025) Assessing the impact of transition and peripheral zone PSA densities over whole-gland PSA density for prostate cancer detection on multiparametric MRI. Prostate. https:\/\/doi.org\/10.1002\/pros.24863","DOI":"10.1002\/pros.24863"},{"key":"12918_CR16","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.euo.2020.12.001","volume":"4","author":"Q Karlsson","year":"2021","unstructured":"Karlsson Q, Brook MN, Dadaev T et al (2021) Rare germline variants in ATM predispose to prostate cancer: a PRACTICAL Consortium study. Eur Urol Oncol 4:570\u2013579. https:\/\/doi.org\/10.1016\/j.euo.2020.12.001","journal-title":"Eur Urol Oncol"},{"key":"12918_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","volume":"77","author":"T Nyberg","year":"2020","unstructured":"Nyberg T, Frost D, Barrowdale D et al (2020) Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Eur Urol 77:24\u201335. https:\/\/doi.org\/10.1016\/j.eururo.2019.08.025","journal-title":"Eur Urol"},{"key":"12918_CR18","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/sj.bjc.6604847","volume":"100","author":"Z Kote-Jarai","year":"2009","unstructured":"Kote-Jarai Z, Jugurnauth S, Mulholland S et al (2009) A recurrent truncating germline mutation in the BRIP1\/FANCJ gene and susceptibility to prostate cancer. Br J Cancer 100:426\u2013430. https:\/\/doi.org\/10.1038\/sj.bjc.6604847","journal-title":"Br J Cancer"},{"key":"12918_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1086\/346094","volume":"72","author":"X Dong","year":"2003","unstructured":"Dong X, Wang L, Taniguchi K et al (2003) Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 72:270\u2013280. https:\/\/doi.org\/10.1086\/346094","journal-title":"Am J Hum Genet"},{"key":"12918_CR20","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/sj.bjc.6605038","volume":"100","author":"J Gronwald","year":"2009","unstructured":"Gronwald J, Cybulski C, Piesiak W et al (2009) Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband. Br J Cancer 100:1508\u20131512. https:\/\/doi.org\/10.1038\/sj.bjc.6605038","journal-title":"Br J Cancer"},{"key":"12918_CR21","doi-asserted-by":"crossref","unstructured":"Ewing CM, Zuhlke KA, Wiley KE et al (2012) Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 366:141\u2013149","DOI":"10.1056\/NEJMoa1110000"},{"key":"12918_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.euros.2025.11.006","volume":"83","author":"L Rodgers-Fouch\u00e9","year":"2026","unstructured":"Rodgers-Fouch\u00e9 L, Kamkari NA, Cruz M et al (2026) Prostate cancer risk and DNA mismatch repair deficiency among Lynch syndrome patients. Eur Urol Open Sci 83:83\u201390. https:\/\/doi.org\/10.1016\/j.euros.2025.11.006","journal-title":"Eur Urol Open Sci"},{"key":"12918_CR23","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1158\/1055-9965.EPI-13-1165","volume":"23","author":"S Ryan","year":"2014","unstructured":"Ryan S, Jenkins MA, Win AK (2014) Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev 23:437\u2013449. https:\/\/doi.org\/10.1158\/1055-9965.EPI-13-1165","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"12918_CR24","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41416-021-01410-0","volume":"125","author":"D Woko\u0142orczyk","year":"2021","unstructured":"Woko\u0142orczyk D, Klu\u017aniak W, Stempa K et al (2021) PALB2 mutations and prostate cancer risk and survival. Br J Cancer 125:569\u2013575. https:\/\/doi.org\/10.1038\/s41416-021-01410-0","journal-title":"Br J Cancer"},{"key":"12918_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2021.10.036","volume":"81","author":"KN Maxwell","year":"2022","unstructured":"Maxwell KN, Cheng HH, Powers J et al (2022) Inherited TP53 variants and risk of prostate cancer. Eur Urol 81:243\u2013250. https:\/\/doi.org\/10.1016\/j.eururo.2021.10.036","journal-title":"Eur Urol"},{"key":"12918_CR26","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2214\/AJR.22.27615","volume":"219","author":"T Barrett","year":"2022","unstructured":"Barrett T, Ghafoor S, Gupta RT et al (2022) Prostate MRI qualification: AJR Expert Panel Narrative Review. AJR Am J Roentgenol 219:691\u2013702. https:\/\/doi.org\/10.2214\/AJR.22.27615","journal-title":"AJR Am J Roentgenol"},{"key":"12918_CR27","doi-asserted-by":"publisher","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA et al (2019) Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol. 76:340\u2013351. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.033","DOI":"10.1016\/j.eururo.2019.02.033"},{"key":"12918_CR28","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1148\/radiol.2018181278","volume":"290","author":"S Mehralivand","year":"2019","unstructured":"Mehralivand S, Shih JH, Harmon S et al (2019) A grading system for the assessment of risk of extraprostatic extension of prostate cancer at multiparametric MRI. Radiology 290:709\u2013719. https:\/\/doi.org\/10.1148\/radiol.2018181278","journal-title":"Radiology"},{"key":"12918_CR29","doi-asserted-by":"publisher","unstructured":"Bancroft EK, Page EC, McHugh J et al (2026) Targeted prostate cancer screening in carriers of BRCA1 or BRCA2 pathogenic germline variants detects clinically relevant disease: 5-year results from the IMPACT study. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2026.01.031","DOI":"10.1016\/j.eururo.2026.01.031"},{"key":"12918_CR30","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","volume":"76","author":"EC Page","year":"2019","unstructured":"Page EC, Bancroft EK, Brook MN et al (2019) Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur Urol 76:831\u2013842. https:\/\/doi.org\/10.1016\/j.eururo.2019.08.019","journal-title":"Eur Urol"},{"key":"12918_CR31","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/s41391-025-00938-z","volume":"28","author":"HV Stroomberg","year":"2025","unstructured":"Stroomberg HV, Brasso K, Blak AA et al (2025) Prostate-specific antigen screening at low thresholds of men with pathogenic BRCA1\/2 variants. Prostate Cancer Prostatic Dis 28:894\u2013901. https:\/\/doi.org\/10.1038\/s41391-025-00938-z","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"12918_CR32","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/S1470-2045(21)00522-2","volume":"22","author":"EK Bancroft","year":"2021","unstructured":"Bancroft EK, Page EC, Brook MN et al (2021) A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet Oncol 22:1618\u20131631. https:\/\/doi.org\/10.1016\/S1470-2045(21)00522-2","journal-title":"Lancet Oncol"},{"key":"12918_CR33","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.eururo.2018.09.021","volume":"75","author":"HB Carter","year":"2019","unstructured":"Carter HB, Helfand B, Mamawala M et al (2019) Germline mutations in ATM and BRCA1\/2 are associated with grade reclassification in men on active surveillance for prostate cancer. Eur Urol 75:743\u2013749. https:\/\/doi.org\/10.1016\/j.eururo.2018.09.021","journal-title":"Eur Urol"},{"key":"12918_CR34","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.eururo.2014.08.007","volume":"67","author":"GP Risbridger","year":"2015","unstructured":"Risbridger GP, Taylor RA, Clouston D et al (2015) Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis. Eur Urol 67:496\u2013503. https:\/\/doi.org\/10.1016\/j.eururo.2014.08.007","journal-title":"Eur Urol"},{"key":"12918_CR35","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/pros.23484","volume":"78","author":"P Isaacsson Velho","year":"2018","unstructured":"Isaacsson Velho P, Silberstein JL, Markowski MC et al (2018) Intraductal\/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer. Prostate 78:401\u2013407. https:\/\/doi.org\/10.1002\/pros.23484","journal-title":"Prostate"},{"key":"12918_CR36","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.eururo.2018.10.009","volume":"75","author":"ES Antonarakis","year":"2019","unstructured":"Antonarakis ES, Shaukat F, Isaacsson Velho P et al (2019) Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations. Eur Urol 75:378\u2013382. https:\/\/doi.org\/10.1016\/j.eururo.2018.10.009","journal-title":"Eur Urol"},{"key":"12918_CR37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejca.2021.01.027","volume":"147","author":"R Lozano","year":"2021","unstructured":"Lozano R, Salles DC, Sandhu S et al (2021) Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer. Eur J Cancer 147:74\u201383. https:\/\/doi.org\/10.1016\/j.ejca.2021.01.027","journal-title":"Eur J Cancer"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-026-12918-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-026-12918-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-026-12918-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:03:17Z","timestamp":1790661797000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-026-12918-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":37,"alternative-id":["12918"],"URL":"https:\/\/doi.org\/10.1007\/s00330-026-12918-5","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"1 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The scientific guarantor of this publication is Rory L. Cochran.","order":1,"name":"Ethics","label":"Guarantor","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Rory L. Cochran, the first author, has statistical expertise relevant to the analyses performed herein.","order":3,"name":"Ethics","label":"Statistics and biometry","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Informed consent was waived by the IRB.","order":4,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Our Institutional Review Board (IRB) approved this study with waiver of informed consent.","order":5,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The present cohort (and its subjects) have not been reported previously.","order":6,"name":"Ethics","label":"Study subjects or cohorts overlap","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"order":7,"name":"Ethics","label":"Methodology","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}